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Background. Infection with hepatitis C virus (HCV) is a burgeoning worldwide public health problem, with
170 million infected individuals and an estimated 20 million deaths in the coming decades. While 6 main geno-
types generally distinguish the global geographic diversity of HCV, a multitude of closely related subtypes within
these genotypes are poorly deﬁned and may inﬂuence clinical outcome and treatment options. Unfortunately, the
paucity of genetic data from many of these subtypes makes time-consuming primer walking the limiting step for
sequencing understudied subtypes.
Methods. Here we combined long-range polymerase chain reaction ampliﬁcation with pyrosequencing for a
rapid approach to generate the complete viral coding region of 31 samples representing poorly deﬁned HCV subtypes.
Results. Phylogenetic classiﬁcation based on full genome sequences validated previously identiﬁed HCV subtypes,
identiﬁed a recombinant sequence, and identiﬁed a new distinct subtype of genotype 4. Unlike conventional sequenc-
ing methods, use of deep sequencing also facilitated characterization of minor drug resistance variants within these
uncommon or, in some cases, previously uncharacterized HCV subtypes.
Conclusions. These data aid in the classiﬁcation of uncommon HCV subtypes while also providing a high-
resolution view of viral diversity within infected patients, which may be relevant to the development of therapeutic
regimens to minimize drug resistance.
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Hepatitis C virus (HCV) is an enveloped, positive-
strand RNA virus belonging to the Hepacivirus genus
in the Flaviviridae family. Seven conﬁrmed genotypes
(1–7) are generally distinguished by phylogenetic
methods and pair-wise distance calculations [1, 2]. On
the basis of full genome nucleotide sequences, HCV
genotypes diverged from each other by a pair-wise dis-
tance of >30%. Individual genotypes can be further
divided into more closely related subtypes that di-
verged by a pair-wise distance of 15%–30%. All viral
genotypes retain their repertoire of colinear structural
and nonstructural genes, thereby facilitating prelimi-
nary genotype classiﬁcation on the basis of partial
genome sequences of short fragments (approximately
300–400 nucleotides) in the structural core/E1 region
and the nonstructural NS5B region [3]. However, full
genome sequences remain indispensible for the detec-
tion of genome recombination events.
While only recombinant HCV genotype 2 k/1b
viruses have been found to actively circulate in the
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population so far [4–7], recombinants of genotypes 2/5, 2b/1b,
2b/1a, and 2i/6p have been detected in single isolates from
humans [8–11]. Furthermore, the frequency of HCV intergen-
otype and intragenotype recombination may be underestimat-
ed because of the lack of robust detection methods [12, 13].
Although genotyping based on core/E1 or NS5B sequences
has resulted in the provisional classiﬁcation of a large number
of subtype variants within each genotype, at least 1 but prefer-
ably ≥2 full genome sequences are required to conﬁrm
subtype designation [2, 12].
Accurate genotype and subtype classiﬁcation is clinically
important because major genotypes differ considerably in
their response rates to treatment with pegylated interferon and
ribavirin and with directly acting antiviral drugs (DAAs) that
are designed mainly against genotype 1 isolates. The limited
efﬁcacy of DAAs against other genotypes has been shown for
genotype 3 [14], and treatment response rates for drug regi-
mens containing boceprevir (an NS3 protease inhibitor) or
BMS-790052 (an NS5A inhibitor) were found to vary even
between subtypes 1a and 1b [15, 16]. Different baseline fre-
quencies of drug resistance mutations may account for these
differences [17], and such variation might become more sig-
niﬁcant if interferon-free regimens containing 1 or more
DAAs could indeed displace the current standard of care [18].
Until clinically tolerable DAAs with high barriers to resistance
against the complete spectrum of HCV genotypes become
available [18, 19], accurate subtype determination and, possi-
bly, drug resistance proﬁling of the individual’s viral popula-
tion may guide the optimal choice of drugs. Full genome deep
sequencing, as performed in this study, allows the identiﬁca-
tion of drug resistance mutations across the genome that may
exist as dominant or minor variants in treatment-naive pa-
tients, thereby informing the design of therapeutic regimens.
METHODS
Sample Collection
Plasma samples obtained from HCV-infected patients in
Canada and the United Kingdom were received with no ac-
companying patient-associated demographic or clinical infor-
mation. This study was approved by the Massachusetts
General Hospital Review Board and was granted exemption by
the Massachusetts Institute of Technology and Massachusetts
General Hospital Review Boards as discarded diagnostic
samples. Preliminary HCV genotypes were assigned by the
clinical centers, and all samples were thought to represent
poorly characterized variants of genotypes 2–4.
Polymerase Chain Reaction (PCR) Ampliﬁcation, Viral Sample
Preparation, and Genome Sequencing
RNA isolation, complementary DNA generation, and PCR
ampliﬁcation within the 5′ untranslated region (UTR) and 3
small sequence islands, followed by ampliﬁcation of 2 hemi-
genome fragments that covered the entire protein coding
region, were performed as previously described [20], using
primers described in Supplementary Table 1. The 5′ UTR and
small sequence islands underwent conventional Sanger se-
quencing. Pooled hemi-genome PCR products were sequenced
by Roche/454, and a de novo assembly was generated as previ-
ously described [21]. Any ambiguities in 454 assemblies were
resolved using Sanger sequencing. All full genome sequences
used in this study have been submitted to Genbank (accession
numbers JX227949–JX227979).
Alignments
All unique, nonrecombinant, full-length HCV genomes found
in the Los Alamos Hepatitis C Sequence Database (http://hcv.
lanl.gov), along with sequences generated in this study, were
used for analyses. For core/E1-NS5B analyses, the Los Alamos
National Laboratory (LANL) HCV database was searched for
all isolates with available sequences for both core/E1 and
NS5B (nucleotide positions 869–1292 and 8276–8615, accord-
ing to genotype 1a reference strain H77). The intersection of
isolates containing both of these sequences was examined on a
genotype and subtype level.
Multiple alignments were performed in MUSCLE v3.8.31
[22], using default parameters with 5 iterative reﬁnements. A
total of 193 full-length genomes (excluding recombinants)
were trimmed to the coding sequence producing a master
alignment of 9323 bases (including gaps). Any gaps in the
triplet of nucleotides underlying codons were removed from
the entire alignment in a greedy fashion, thereby conservative-
ly eliminating any alignment artifacts. For the genotyping
fragment trees that included 300 viral strains for which both
regions of core/E1 (869–1292) and NS5B (8276–8615) were
available, these regions were concatenated into an alignment
of 779 nucleotides (including gaps). No gap stripping was per-
formed on the genotyping fragment sequences.
Identiﬁcation of Recombinants
The recombination detection program (RDP) [23] was run on
all full-length genome sequences representing all available ge-
notypes and subtypes. Any sequences that produced consis-
tently low P values among the RDP’s multiple tests for
recombination were subject to further analysis. These potential
recombinant sequences were further validated with SimPlot
v3.5.1 [24], in which all possible combinations of major and
minor parent strains were run against the recombinant strain.
Construction of Phylogenetic Trees
The randomized axelerated maximum likelihood program
[25] was run with 1000 bootstraps to construct a single tree
for the 193 genomes mentioned above, using the cleaned
alignment containing 3753 bases. The smaller genotyping
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trees of 300 concatenated fragments spanning 779 nucleotides
were used in the same manner. The GTRGAMMA model was
chosen as the model of nucleotide substitution. The single best
tree from the 1000 bootstraps is shown, along with the total
percentage (0%–100%) of bootstrap support for each branch.
Computation of Pair-Wise Intersubtype and Intrasubtype
Divergence
Pair-wise distances for all 193 full-length nonrecombinant
genomes were calculated in MEGA v.5.05 [26].
The PhyloPlace tool was used to compute the branching
index over the length of our 2 putative subtype 4v genomes
(http://hcv.lanl.gov/content/sequence/phyloplace/PhyloPlace.
html).
Variant Calling in Mixed Populations
Prior to variant calling, correction of known error modes in
Roche/454 read data was performed with the RC454 program
[21]. Reliable and sensitive detection of variants in a mixed
population and analysis of intrahost diversity was then accom-
plished using the VPhaser tool [27].
RESULTS
Phylogenetic Classiﬁcation of HCV Genotypes Based on Full-
Genome Sequences
To better characterize global HCV genotype diversity, sequenc-
es representing the entire HCV protein-coding region and por-
tions of the 5′ and 3′ UTR were generated from plasma
samples acquired from 54 patients in Canada or the United
Kingdom. Preliminary HCV genotyping based on core/E1 or
NS5B sequences indicated that these individuals were infected
with poorly characterized subtypes of genotypes 2, 3, or 4. Use
of a hemi-genome ampliﬁcation approach [20], coupled with
high-throughput pyrosequencing technology, enabled genera-
tion of sequence reads covering the entire coding region
without the need for traditional primer-walking methods. The
success rate for ampliﬁcation of both hemi-genomes from the
54 samples attempted was 83%, with 31 samples being used for
sequencing. A recently developed algorithm allowed de novo
assembly of all 31 genomes, despite the lack of full-length refer-
ence sequences for these poorly characterized genotypes [21].
Genome sequences were aligned to all available full-length
sequences from the National Center for Biotechnology Infor-
mation and LANL public databases, including select represen-
tatives of the commonly found 1a or 1b subtypes.
Phylogenetic analysis revealed that several of the new se-
quences clustered with subtypes for which only 1 full-length
genome sequence had been reported (2c, 2k, 3i, 4g, 4l, 4m, 4n,
4o, and 4r), thereby strengthening these phylogenetic group-
ings (Figure 1), with pair-wise distance measurements con-
ﬁrming their distinction from other subtypes (Table 1).
Sequences provisionally assigned to the 2 m and 3 g subtypes
on the basis of partial sequence grouped accordingly, formally
establishing these as distinct HCV subtypes (Figures 1 and 2).
Likewise, quantiﬁcation of relatedness to all known subtypes
by branching index analysis (Supplementary Figure 1),
coupled with 100% bootstrap support by phylogeny (Figure 1)
and pair-wise distance measurements (Table 1), clearly
grouped 2 newly described genotype 4 sequences, G1248/
PB66742 and G1249/PB65568, to near full-length genomes
from the recently identiﬁed 4v provisional subtype [28],
thereby conﬁrming 4v as a distinct subtype of genotype 4.
In addition to validating previously identiﬁed HCV genetic
subtypes, phylogenetic analysis also identiﬁed a novel geno-
type 4 variant. While isolate G1253/PB53414 grouped with ge-
notype 4 sequences in the full-genome phylogenetic tree
(Figure 1), bootstrap resampling strongly supported G1253/
PB53414 as a unique subtype as compared to genotypes 4g
and 4k (Figure 1). Similarly, G1253/PB53414 was genetically
distinct from subtypes 4h, 4g, and 4k in the core/E1-NS5B
tree (Figure 2). In addition, nucleotide sequence divergence of
G1253/PB53414 from all other genotype 4 full genome se-
quences was >17.7% (Table 1). These lines of evidence
strongly suggest that G1253/PB53414 represents a novel
subtype of a genotype 4. This new genotype 4 variant could be
designated as subtype 4w, but since only 1 example of this
subtype has been sequenced, accepted convention for assign-
ing provisional subtypes calls for designation of G1253/
PB53414 as an unclassiﬁed genotype 4 variant.
One recombinant sequence was also identiﬁed. SimPlot
analysis showed G1241/PB41880 to be a recombinant between
subtypes 2k (K1-S2/AB031663) and 1b (Vat-96/D50485),
sharing a recombination break point with 2k/1b recombi-
nants previously identiﬁed in St. Petersburg, CRF_01_1b2k
(Figure 3). Despite high sequence identity (93%–94%), G1241/
PB41880 is not identical to previously reported 2k/1b recom-
binants. Nevertheless, separate phylogenetic analysis of 2k and
1b components of the new strain identiﬁed here along with
other nonrecombinant 2k and 1b sequences conﬁrm that
there is 100% bootstrap support for G1241/PB41880 grouping
with all other reported 2k/1b strains (Figure 4).
In the case of subtypes 2 m and 3 g, for which no full genome
sequences were available in public databases, classiﬁcation of
these new sequences on the basis of genotyping regions alone was
clearly supported (Figure 2). As expected, in instances where both
full genome and partial genome data were available, bootstrap
support for subtype classiﬁcation was stronger in full-genome
trees as compared to partial genome trees (Figures 1 and 2).
Prevalence of Dominant, Naturally Occurring Polymorphisms
at Positions Associated with Drug Resistance
Alignments of these full genome sequences allowed us to in-
vestigate the prevalence of dominant amino acid substitutions
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Figure 1. Maximum likelihood tree of 30 complete, nonrecombinant hepatitis C virus coding-region nucleotide sequences generated as part of this
study (highlighted in blue), and 163 sequences from public sequence repositories. Bootstrap resampling (1000 replications) support values are shown at
nodes. The tree is rooted using genotype 1 sequences, and all horizontal branch lengths are drawn to a scale of nucleotide substitutions per site.
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Table 1. Average Internucleotide and Intranucleotide Divergence Among Hepatitis C Virus Subtypes
Genotype 1 1a (2) 1b (3) 1c (3) 1g (1)
1a (2) 0.73 21.41 19.23 21.51 … … … … … … … … … … … … … … … … … … …
1b (3) 21.41 8.36 22.26 22.02 … … … … … … … … … … … … … … … … … … …
1c (3) 19.23 22.26 8.16 22.31 … … … … … … … … … … … … … … … … … … …
1g (1) 21.51 22.02 22.31 — … … … … … … … … … … … … … … … … … … …
Genotype 2 2a (18) 2b (14) 2c (6) 2i (1) 2k (2) 2m (3)
2a (18) 7.96 23.08 19.75 19.37 20.37 19.44 … … … … … … … … … … … … … … … … …
2b (14) 23.08 6.63 22.56 22.93 23.44 22.27 … … … … … … … … … … … … … … … … …
2c (6) 19.75 22.56 9.39 18.86 19.82 19.12 … … … … … … … … … … … … … … … … …
2i (1) 19.37 22.93 18.86 — 19.89 19.53 … … … … … … … … … … … … … … … … …
2k (2) 20.37 23.44 19.82 19.89 9.67 19.04 … … … … … … … … … … … … … … … … …
2m (3) 19.44 22.27 19.12 19.53 19.04 7.83 … … … … … … … … … … … … … … … … …
Genotype 3 3a (7) 3b (1) 3g (1) 3i (4) 3k (1)
3a (7) 6.20 21.75 20.78 21.04 24.78 … … … … … … … … … … … … … … … … … …
3b (1) 21.75 — 20.29 19.67 25.36 … … … … … … … … … … … … … … … … … …
3g (1) 20.78 20.29 — 19.41 25.11 … … … … … … … … … … … … … … … … … …
3i (4) 21.04 19.67 19.41 5.55 24.33 … … … … … … … … … … … … … … … … … …
3k (1) 24.78 25.36 25.11 24.33 — … … … … … … … … … … … … … … … … … …
Genotype 4 4a (16) 4b (4) 4c (1) 4d (4) 4f (6) 4g (3) 4k (3) 4l (3) 4m (3) 4n (3) 4o (4) 4p (1) 4q (1) 4r (4) 4t (1) 4v (4) 4∼ (1)
4a (16) 7.45 20.61 14.61 17.99 18.54 20.00 19.99 18.01 18.72 18.67 18.43 18.78 17.87 20.39 19.32 18.19 20.26 … … … … … …
4b (4) 20.61 15.24 20.73 21.07 20.76 20.16 20.19 20.61 21.13 20.94 21.00 20.74 20.09 20.49 21.27 20.44 20.02 … … … … … …
4c (1) 14.61 20.73 — 18.05 18.65 20.19 20.11 17.79 18.27 18.31 18.54 18.35 17.53 20.78 18.79 18.04 19.79 … … … … … …
4d (4) 17.99 21.07 18.05 6.52 19.20 20.91 20.43 18.27 18.66 19.25 18.76 19.11 18.02 21.06 19.78 18.60 20.01 … … … … … …
4f (6) 18.54 20.76 18.65 19.20 8.16 20.31 20.40 19.00 19.38 19.39 19.30 18.93 18.56 20.55 19.39 19.15 20.07 … … … … … …
4g (3) 20.00 20.16 20.19 20.91 20.31 11.18 16.83 20.63 20.60 20.26 20.10 20.62 19.88 17.80 20.82 20.02 17.70 … … … … … …
4k (3) 19.99 20.19 20.11 20.43 20.40 16.83 8.19 20.56 20.70 20.28 20.55 20.78 20.19 18.88 20.95 20.24 18.25 … … … … … …
4l (3) 18.01 20.61 17.79 18.27 19.00 20.63 20.56 7.85 18.69 18.46 18.76 18.55 15.83 20.72 19.03 16.50 19.81 … … … … … …
4m (3) 18.72 21.13 18.27 18.66 19.38 20.60 20.70 18.69 7.79 18.91 19.11 18.76 18.22 20.61 19.37 18.57 20.41 … … … … … …
4n (3) 18.67 20.94 18.31 19.25 19.39 20.26 20.28 18.46 18.91 8.28 19.13 19.34 17.28 20.58 19.55 18.18 20.19 … … … … … …
4o (4) 18.43 21.00 18.54 18.76 19.30 20.10 20.55 18.76 19.11 19.13 8.02 19.27 18.16 20.42 19.76 18.67 20.02 … … … … … …
4p (1) 18.78 20.74 18.35 19.11 18.93 20.62 20.78 18.55 18.76 19.34 19.27 — 18.41 20.52 14.72 18.55 20.52 … … … … … …
4q (1) 17.87 20.09 17.53 18.02 18.56 19.88 20.19 15.83 18.22 17.28 18.16 18.41 — 20.52 18.37 14.30 19.62 … … … … … …
4r (4) 20.39 20.49 20.78 21.06 20.55 17.80 18.88 20.72 20.61 20.58 20.42 20.52 20.52 7.87 21.20 21.07 18.28 … … … … … …
4t (1) 19.32 21.27 18.79 19.78 19.39 20.82 20.95 19.03 19.37 19.55 19.76 14.72 18.37 21.20 — 19.04 21.12 … … … … … …
4v (4) 18.19 20.44 18.04 18.60 19.15 20.02 20.24 16.50 18.57 18.18 18.67 18.55 14.30 21.07 19.04 6.67 20.21 … … … … … …
4∼ (1) 20.26 20.02 19.79 20.01 20.07 17.70 18.25 19.81 20.41 20.19 20.02 20.52 19.62 18.28 21.12 20.21 — … … … … … …
Genotype 5 5a (2)
5a (2) 9.43 … … … … … … … … … … … … … … … … … … … … … …
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Table 1 continued.
Genotype 6 6a (16) 6b (1) 6c (1) 6d (1) 6e (4) 6f (3) 6g (2) 6h (1) 6i (3) 6j (2) 6k (4) 6l (2) 6m (4) 6n (4) 6o (2) 6p (1) 6q (1) 6r (1) 6s (1) 6t (4) 6u (1) 6v (1) 6w (1)
6a (16) 5.32 19.92 26.53 27.07 27.14 27.02 27.09 26.99 26.85 27.04 26.76 26.18 26.68 26.98 26.09 26.14 25.60 26.87 27.14 27.09 26.36 26.77 27.40
6b (1) 19.92 — 26.54 26.85 26.98 26.96 26.85 27.03 27.40 26.93 26.89 26.71 26.56 26.83 26.41 26.22 25.90 26.63 27.10 26.84 26.64 26.80 27.31
6c (1) 26.53 26.54 — 20.89 22.45 22.40 25.02 26.47 25.70 26.26 25.09 25.38 25.42 25.48 21.68 21.46 21.19 22.39 25.40 22.32 25.38 26.30 26.07
6d (1) 27.07 26.85 20.89 — 22.59 22.79 25.43 26.47 26.32 26.31 26.11 25.78 25.61 25.50 22.39 22.32 21.75 22.36 24.83 22.42 25.16 26.64 26.54
6e (4) 27.14 26.98 22.45 22.59 14.49 22.99 25.46 26.46 26.24 26.24 26.43 25.96 26.27 25.88 21.84 21.80 21.17 23.54 25.21 22.19 25.53 27.24 26.01
6f (3) 27.02 26.96 22.40 22.79 22.99 4.14 25.15 26.50 26.44 26.09 25.91 25.61 25.72 25.75 22.43 22.86 21.64 17.26 25.25 22.61 25.59 26.36 25.93
6g (2) 27.09 26.85 25.02 25.43 25.46 25.15 6.70 26.74 26.98 26.77 26.71 25.98 26.58 26.33 25.68 25.57 24.52 25.76 26.25 25.48 26.74 27.31 24.69
6h (1) 26.99 27.03 26.47 26.47 26.46 26.50 26.74 — 20.99 20.47 23.00 22.59 22.63 22.38 26.08 26.12 25.07 26.59 26.96 26.48 26.55 26.52 27.29
6i (3) 26.85 27.40 25.70 26.32 26.24 26.44 26.98 20.99 5.13 17.04 23.50 22.63 22.51 22.68 25.76 25.25 24.60 26.39 26.67 25.97 26.40 26.29 27.23
6j (2) 27.04 26.93 26.26 26.31 26.24 26.09 26.77 20.47 17.04 3.26 23.25 22.44 22.79 22.58 26.30 26.05 24.75 26.46 26.70 26.14 25.89 26.45 27.00
6k (4) 26.76 26.89 25.09 26.11 26.43 25.91 26.71 23.00 23.50 23.25 10.47 19.00 21.42 21.54 26.13 25.60 24.95 26.38 26.35 26.19 25.66 26.30 26.55
6l (2) 26.18 26.71 25.38 25.78 25.96 25.61 25.98 22.59 22.63 22.44 19.00 4.94 21.26 20.93 25.74 25.33 24.26 25.78 25.96 25.53 25.46 25.74 26.72
6m (4) 26.68 26.56 25.42 25.61 26.27 25.72 26.58 22.63 22.51 22.79 21.42 21.26 3.30 18.82 25.30 25.16 24.51 25.76 26.27 25.57 25.43 25.74 26.91
6n (4) 26.98 26.83 25.48 25.50 25.88 25.75 26.33 22.38 22.68 22.58 21.54 20.93 18.82 5.03 25.08 24.86 23.93 25.47 26.27 25.61 25.47 26.18 26.85
6o (2) 26.09 26.41 21.68 22.39 21.84 22.43 25.68 26.08 25.76 26.30 26.13 25.74 25.30 25.08 7.52 19.54 20.81 22.81 24.70 21.27 25.30 25.87 25.71
6p (1) 26.14 26.22 21.46 22.32 21.80 22.86 25.57 26.12 25.25 26.05 25.60 25.33 25.16 24.86 19.54 — 20.94 22.70 25.09 21.39 25.56 26.47 26.00
6q (1) 25.60 25.90 21.19 21.75 21.17 21.64 24.52 25.07 24.60 24.75 24.95 24.26 24.51 23.93 20.81 20.94 — 21.53 23.84 20.32 25.25 24.94 24.59
6r (1) 26.87 26.63 22.39 22.36 23.54 17.26 25.76 26.59 26.39 26.46 26.38 25.78 25.76 25.47 22.81 22.70 21.53 — 24.76 22.79 25.86 26.57 25.97
6s (1) 27.14 27.10 25.40 24.83 25.21 25.25 26.25 26.96 26.67 26.70 26.35 25.96 26.27 26.27 24.70 25.09 23.84 24.76 — 25.01 25.88 27.02 26.39
6t (4) 27.09 26.84 22.32 22.42 22.19 22.61 25.48 26.48 25.97 26.14 26.19 25.53 25.57 25.61 21.27 21.39 20.32 22.79 25.01 7.51 25.71 26.02 25.75
6u (1) 26.36 26.64 25.38 25.16 25.53 25.59 26.74 26.55 26.40 25.89 25.66 25.46 25.43 25.47 25.30 25.56 25.25 25.86 25.88 25.71 — 24.58 27.14
6v (1) 26.77 26.80 26.30 26.64 27.24 26.36 27.31 26.52 26.29 26.45 26.30 25.74 25.74 26.18 25.87 26.47 24.94 26.57 27.02 26.02 24.58 — 27.20
6w (1) 27.40 27.31 26.07 26.54 26.01 25.93 24.69 27.29 27.23 27.00 26.55 26.72 26.91 26.85 25.71 26.00 24.59 25.97 26.39 25.75 27.14 27.20 —
Data are no. of base differences per sequence (divided by total no. of positions [ie, 9314] in the master alignment) from between sequences. The analysis involved 193 nucleotide sequences. All ambiguous positions
were removed for each sequence pair. Numbers in parentheses next to subtype names indicate no. of genomes of each subtype included in pair-wise analysis. Bold text shows distances within a given subtype.
Subtypes with <2 sequences for comparison are denoted by—.
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Figure 2. Maximum likelihood tree based on concatenated core/E1 (869–1292 on H77 reference) and NS5B (8276–8615 on H77 reference) nucleotide
sequences. Hepatitis C virus sequences are designated by accession number or sequence ID, followed by subtype designation and unique name. Sequences
for the 30 nonrecombinant isolates described in this study are colored in blue. Bootstrap resampling (1000 replications) support values are shown at nodes.
The tree is rooted using genotype 1 sequences, and all horizontal branch lengths are drawn to a scale of nucleotide substitutions per site.
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among rare HCV subtypes and identify those known to be as-
sociated with resistance to NS3 protease and NS5B polymerase
inhibitors (Table 2). In NS3, the V36L substitution that
confers resistance to telaprevir [29] was found to be dominant
in 100% of genotype 2–5 sequences analyzed, the single geno-
type 7 sequence analyzed, and 20% of genotype 6 sequences
analyzed, while the A39V substitution responsible for resis-
tance to ACH-806 [30], was dominant in 100% of genotype 2
sequences analyzed. Moreover, all genotype 3 sequences and
the 1 available genotype 7 sequence analyzed contained a D to
Q substitution at amino acid 168, a site at which other muta-
tions conferring up to 10 000-fold resistance to TMC-435 have
been described in HCV genotype 1 [31]. Additionally, a
D168E substitution known to confer 40-fold resistance to
TMC-435 was found in 1 of 2 genotype 5 sequences and in 2
of 62 genotype 6 sequences [31]. In rare instances, we also
identiﬁed genomes with dominant drug resistance mutations
at positions C16, T54, A156, or V170 (Table 2).
In NS5B, the M414L substitution conferring resistance to
the polymerase inhibitor A-782759 was found in 53% of geno-
type 4 sequences spanning multiple subtypes. The S282T mu-
tation associated with resistance to the nucleoside analog
mericitabine and the nucleotide analog PSI-7977 [37] was
found to be dominant in only one of the 191 sequences ana-
lyzed, a previously described genotype 4a isolate (ED43) from
Egypt [32]. A small number of genomes harboring dominant
drug resistance mutations at positions N411, M423, P495, and
G554 were also identiﬁed (Table 2).
Combinations of dominant resistance mutations in NS3
and/or NS5B were found in genotype 2 (NS3:V36L and
A39V), genotype 3 (NS3:V36L, and D168Q), and genotype 4
(NS3:V36L and M414L) sequences, suggesting possible resis-
tance to multiple antiviral drugs (telaprevir/ACH806, telapre-
vir/TCM-435, and telaprevir/A-782759, respectively). Further
examination of the highly polymorphic residue 414 of NS5B
in genotype 4 sequences revealed a subtype-speciﬁc pattern
Figure 3. Recombination similarity plot of the 2k/1b recombinant genome. Colored lines indicate the percentage identity (y-axis) of G1253 to each of
9 full-length nonrecombinant genomes across the entire genome (x-axis).
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Figure 4. Phylogenetic analysis of genotype 2k and genotype 1b sequences composing the G1241/PB41880 2k/1b recombinant. Hepatitis C virus
sequences are designated by accession number, followed by subtype. A, Maximum likelihood tree of 2k nucleotide sequences corresponding to nucleo-
tides 1–3291 of the G1241/PB41880 open reading frame (ORF). B, Maximum likelihood tree of 1b nucleotide sequences corresponding to nucleotides
3292–8926 of the G1241/PB41880 ORF. Genomes corresponding to other conﬁrmed 2k/1b recombinants are colored in blue, while G1241/PB41880 is
colored in red. Bars, 0.2 nucleotide substitutions per site. Black text denotes sequences from nonrecombinant genomes.
Pyrosequencing of Rare HCV Genotypes • JID 2013:208 (1 July) • 25
Table 2. Dominant Mutations Associated With Resistance to NS3 Protease and NS5B Polymerase Inhibitors in Complete Genome Sequences of Hepatitis C Virus Genotypes 1–7
Protein
Amino
Acid
Position
Dominant
Amino
Acid
Mutant
Amino
Acid Drug
Substitution (% of Genomes), by Genotype
Genotype 1
(n = 9)
Genotype 2
(n = 43)
Genotype 3
(n = 14)
Genotype 4
(n = 62)
Genotype 5
(n = 2)
Genotype 6
(n = 61)
Genotype
7 (n = 1)
NS3 16 C S ACH806 ▪ A (77)/S (2)/T
(21)
T (100) A (100) T (100) T (100)
NS3 36 V AMLG Telaprevir,
boceprevir,
SCH900518
▪ L (100) L (100) L (100) L (100) V (75)/L (20)/ I (5) L (100)
NS3 39 A V ACH806 ▪ V (98)/I (2) A (65)/S
(14)/T (21)
A (92)/T (8) ▪ A (97)/T (1.5)/ D (1.5) S (100)
NS3 41 Q R Boceprevir,
ITMN-191
▪ ▪ ▪ ▪ ▪ ▪ ▪
NS3 43 F SC ITMN-191,
telaprevir,
boceprevir
▪ ▪ ▪ ▪ ▪ ▪ ▪
NS3 54 T AS Telaprevir,
boceprevir,
SCH900518
T (89)/S (11) ▪ ▪ T (97)/S (3) ▪ ▪ G (100)
NS3 109 R K SCH6 ▪ ▪ ▪ R (100) ▪ ▪ ▪
NS3 138 S T ITMN-191 ▪ ▪ ▪ S (98)/F (2) ▪ S (98.5)/F (1.5) ▪
NS3 155 R K,T,I,M,
G,L,S,Q
Telaprevir,
boceprevir, TMC
435, R7227, MK
7009, BI 201335,
SCH900518,
BILN-2061
▪ ▪ ▪ ▪ ▪ ▪ ▪
NS3 156 A STVI Telaprevir,
boceprevir,
R7227,
SCH900518,
BILN-2061
▪ ▪ ▪ ▪ ▪ A (98.5)/V (1.5) ▪
NS3 168 D QAVET TMC 435, R7227,
MK 7009,
BI201335, BILN-
2061
▪ ▪ Q (100) ▪ D (50)/E (50) D (97)/E (3) Q (100)
NS3 170 V AT Telaprevir,
boceprevir
V (56)/I (44) I (95)/V (2.5)
/unresolved
(2.5)
I (71)/V (29) V (97)/I (3) I (50)/V (50) V (65.5)/A (1.5)/I (33) ▪
NS3 489 S L ITMN-191 S (67)/V (33) V (100) V (100) S (89)/A (9)/V (2) V (100) V (85)/I (15) ▪
NS5B 95 H Q A-782759 ▪ ▪ ▪ ▪ ▪ H (97)/C (1.5)/R (1.5) ▪
NS5B 96 S T R1479 ▪ ▪ ▪ ▪ ▪ ▪ ▪
NS5B 282 S T 2’C-methyl-
ribonucleosides
▪ ▪ ▪ S (98)/T (2) ▪ ▪ ▪
NS5B 316 C Y HCV-796, A-837093 C (89)/N (11) C (98)/W (2) ▪ C (87)/N (8)/H
(5)
▪ ▪ ▪
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Table 2 continued.
Protein
Amino
Acid
Position
Dominant
Amino
Acid
Mutant
Amino
Acid Drug
Substitution (% of Genomes), by Genotype
Genotype 1
(n = 9)
Genotype 2
(n = 43)
Genotype 3
(n = 14)
Genotype 4
(n = 62)
Genotype 5
(n = 2)
Genotype 6
(n = 61)
Genotype
7 (n = 1)
NS5B 365 S TA HCV-796 ▪ ▪ ▪ ▪ ▪ ▪ ▪
NS5B 411 N S A-782759 ▪ ▪ N (93)/S (7) ▪ ▪ ▪ ▪
NS5B 414 M LT A-782759 ▪ Q (98)a ▪ L (53)/V (32)/I
(13)/Q (2)
▪ M (98.5)/A (1.5) ▪
NS5B 423 M TVI AG-021541 ▪ ▪a ▪ ▪ I (100) ▪ ▪
NS5B 448 Y HC A-782759, A-
837093
▪ ▪a ▪ ▪ ▪ ▪ ▪
NS5B 495 P LA JTK-109 ▪ ▪a,b ▪c ▪e ▪ P (98.5)/L (1.5) ▪
NS5B 554 G DS A-837093 ▪ G (74)/S
(21)a,b
▪c,d ▪e,f ▪ ▪ C (100)
NS5B 559 D GSN A-837093 ▪ D (93)/H (2)a,b ▪c,d ▪e,f ▪ ▪ ▪
Filled squares indicate that the dominant residue found in genotype 1 is found in 100% of the genomes analyzed for any given genotype. Substitutions known to confer drug resistance are in bold, and substitutions of
unknown impact are in italics.
Abbreviation: AA, amino acid.
a No data at this position for G1727_2m_QC76.
b No data at this position for DQ430815_2b_TN9-0FL.
c No data at this position for AY956467_3a_32E and DQ430819_3a_TN78-0.
d No data at this position for G1245_3i_PB98686.
e No data at this position for DQ988079_4a_Eg12 and DQ988073_4a_Eg2.
f No data at this position for EF589160_4f_IFBT84, DQ988074_4a_Eg3, DQ988075_4a_Eg4, DQ988076_4a_Eg7, DQ988077_4a_Eg9, DQ988078_4a_Eg10, and G1726_4n_PB58378.
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whereby all subtype 4g, 4k-4r, and 4v genomes and 3 of 4
subtype b sequences had the M414L mutation reported to
confer resistance to A-782759, while the remaining subtypes
(a, c, d, f, and t) harbored multiple variants of unknown phe-
notype (M414I, M414Q, or M414V; Table 2 and Supplemen-
tary Table 2).
In addition to known resistance changes, other dominant
substitutions of unknown resistance status were also common
at key sites in NS3 and NS5B (Table 2). The dominant residue
at amino acid 16 of NS3 was cysteine, in genotype 1, but was
alanine, in genotypes 2 (74.4%) and 5 (100%), and threonine,
in genotypes 4 and 6 (both 100%). The dominant NS3 V170
residue found in genotype 1 was an isoleucine, in 95% of ge-
notype 2 and 71% of genotype 3 sequences. Isoleucine was
also found at this position in genotypes 4–6, although at lower
frequency (3%–50%). All genotype 2 and 3 sequences had a
valine at residue 489 in NS3, rather than the serine found in
genotype 1. Finally, the M414 in NS5B was replaced with glu-
tamine, in 100% of genotype 2 sequences, and with isoleucine,
in 32% of genotype 4 sequences.
Analysis of Viral Populations for Minor Variants at Drug
Resistant Sites
The average depth of coverage generated by pyrosequencing
across all 31 samples ranged from 2 to 3200 across the com-
plete HCV genome and from 22 to 3041 at the drug resistance
sites analyzed in NS3 and NS5B. This led to the identiﬁcation
of minor variants at drug resistance sites in NS3 in 7 of 31
samples. Minor variants ranged in frequency, from 0.10% to
7.78% (Table 3). Only the dominant amino acid was detected
in the remaining 24 sequences, despite 500–900-fold sequence
coverage. Even within genomes with extremely high sequence
coverage, no minor variants were detected at known drug re-
sistance sites in NS5B. It is possible that sequencing genomes
to higher coverage could result in identiﬁcation of additional
low-frequency mutations at these drug resistance sites. Fur-
thermore, we cannot exclude the possibility that some muta-
tions were not detected because of primer selection bias.
The viral population of 3 individuals contained single low-
frequency polymorphisms in NS3 that have been associated
with resistance to BI-201335 or SCH-900518 (G1251/
PB80852:D168E, G1314/QC104:A156V, and G2035/PB83515:
D168E). One individual (G2036/PB84975) had multiple mu-
tations (A29V, T54A, A156T, and V170A) associated with
resistance to the protease inhibitors ACH806, telaprevir, boce-
previr, SCH-900518, or R7227. The viral populations also con-
tained variants of unknown phenotype at key sites in NS3
(Table 3). One individual, G2037/PB57078, harbored low-fre-
quency HCV variants L36P/R altering the dominant leucine
that is associated with drug resistance to mutations of
unknown drug response status.
DISCUSSION
In this study, we report the use of pyrosequencing combined
with a hemi-genome ampliﬁcation approach to rapidly se-
quence, assemble, and classify 30 complete HCV genome se-
quences of poorly characterized HCV subtypes (2c, 2k, 2m,
3g, 3i, 4g, 4l, 4m, 4n, 4o, 4r, and 4v) and 1 intergenotypic
recombinant (2k/1b) for a better view of global sequence di-
versity, enabling formal conﬁrmation of the provisionally clas-
siﬁed HCV subtypes 2c, 3g, and 4v and the identiﬁcation of a
novel variant of genotype 4. Together with sequences available
from public databases, these new data enhance our knowledge
of potential drug resistance mutations, especially for subtypes
of genotypes 2 and 4 that are mainly found on the African
continent [2]. Pyrosequencing of HCV hemi-genomes,
without previous knowledge of target sequence or use of time-
consuming and labor-intensive methods such as primer
walking, allowed a high-resolution assessment of both high-
frequency and low-frequency drug resistance mutations across
the full viral genome in infected individuals.
The importance of accurate HCV genotyping, with at least
1 full genome sequence required to resolve discrepancies in
HCV subtype classiﬁcation, has been emphasized for the
study of HCV evolution and potential associations with treat-
ment response to DAAs [2, 12, 28, 33–37]. Unlike core-E1/
NS5B genotyping, analysis of full genome sequences allows
identiﬁcation of divergence across all regions of the genome,
thereby facilitating parsing of closely related, yet distinct
subtype sequences. This is further evidenced in our phyloge-
netic analysis by the increase in bootstrap support for subtype
assignments based on full genome sequences as compared to
assignments based on core-E1/NS5B sequences. As a result,
we are able to provide deﬁnitive conﬁrmation of several provi-
sionally classiﬁed subtypes and to identify a potential novel
subtype of genotype 4. We expect that as more full genome
sequences become available, new HCV subtypes will be teased
apart from existing ones and that additional nomenclature cri-
teria will be necessary.
The ability to robustly identify and classify genotype recom-
binants in full genome sequences is also critical in determin-
ing the prevalence and clinical relevance of such genetic
events. The genotype 2k/1b recombinant sequenced here,
G1241/PB41880, appears to be a member of the same circulat-
ing recombinant form as that identiﬁed in St. Petersburg [4,
5]. However, despite sharing the same mosaic structure as the
St. Petersburg isolate, phylogenetic and break point site evi-
dence suggests that G1241/PB41880 is likely to be an indepen-
dently transmitted and diverged copy of the previously
observed recombinant type, rather than a novel recombinant
of similar parental strains.
Dominant drug resistance mutations in response to treat-
ment with DAAs have been extensively studied in genotype 1
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Table 3. Minor Variants at Amino Acids (AAs) Associated With Resistance to NS3 Protease Inhibitors in the Viral Population of Patients Infected With Hepatitis C Virus
Position
Dominant AA in
Genotype 1
Mutant AA in
Genotype 1 Drug Sample Genotype
Dominant AA
(Frequency)
Minor AA
(Frequency)
Fold-Sequence
Coverage
16 C S ACH806 G2035/PB83515 4r T (98.86) A (1.14) 2458
36 V AMLG Telaprevir, boceprevir, SCH900518 G2037/PB57078 4o L (99.51) P (0.2)/R (0.10) 3030
39 A V ACH806 G2036/PB84975 4r A (99.39) V (0.61) 2300
43 F SC ITMN-191, telaprevir, boceprevir G2038/PB63548 4o F (98.21) L (1.79) 2345
F SC ITMN-191, telaprevir, boceprevir G2039/PB63590 4o F (98.77) L (1.23) 2690
F SC ITMN-191, telaprevir, boceprevir G2037/PB57078 4o F (99.34) L (0.66) 3041
54 T AS Telaprevir, boceprevir, SCH900518 G2036/PB84975 4r T (99.55) P (0.45)/A (0.11) 2537
109 R K SCH6 G2036/PB84975 4r R (99.89) Q (0.11) 2717
155 R K,T,I,M,G,L,
S,Q
Telaprevir, boceprevir, TMC 435,
R7227,
MK 7009, BI 201335,
SCH900518,
BILN-2061
G2036/PB84975 4r R (99.89) W (0.11) 2846
156 A STVI Telaprevir, boceprevir, R7227,
SCH900518, BILN-2061
G1314/QC104 2m A (92.22) V (7.78) 90
A STVI Telaprevir, boceprevir, R7227,
SCH900518, BILN-2061
G2036/PB84975 4r A (99.86) T (0.14) 2066
168 D QAVET TMC 435, R7227, MK 7009,
BI201335, BILN-2061
G1251/PB80852 4r D (94.64) E (5.36) 56
D QAVET TMC 435, R7227, MK 7009,
BI201335,
BILN-2061
G2035/PB83515 4r D (99.7) E (0.3) 2109
170 V AT Telaprevir, boceprevir G2036/PB84975 4r V (99.61) A (0.39) 2818
Substitutions known to confer drug resistance are in bold, and substitutions of unknown impact are in italics.
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infection, but data on drug resistance mutations in other geno-
types remain scarce [38–40]. Furthermore, very few studies
explore sensitive techniques for the identiﬁcation of minor
drug resistance variants in viral populations [41]. The applica-
tion of pyrosequencing to poorly characterized HCV genotypes
allowed the identiﬁcation of naturally occurring genotype and
subtype-speciﬁc drug resistance mutations to mutations confer-
ring resistance to DAAs, as well as a high-resolution view of
intrapatient sequence diversity. In these poorly described HCV
genotypes, we ﬁnd a genotype and subtype-speciﬁc distribution
of dominant changes in key resistance sites in NS3 and NS5B
proteins, as well as minor variants in NS3. While mutations at
drug resistance sites in NS3 in genotypes 2–5 have been previ-
ously reported [39, 40], this study extends the analysis to resis-
tance mutations in NS5B and includes genotype 6 and 7
sequences in the analysis.
The availability of full genome sequences also allowed the
identiﬁcation of genotype 4 subtypes that harbor resistance mu-
tations in both NS3 (V36L) and NS5B (M414L) that have been
associated with increased resistance to treatment with telaprevir
and A-782759. The presence of both of these dominant resis-
tance mutations in subtype 4g, 4k-4r, and 4v virus isolated from
infected patients suggests that these patients might respond
poorly to treatment with both drugs, although this remains to be
tested. Furthermore, the ﬁnding that these 2 changes are found
only in a subset of genotype 4 subtypes reinforces the impor-
tance of subtype classiﬁcation in helping to predict clinical re-
sponse to treatment, as has recently been found for treatment
response rates to DAAs for HCV subtypes 1a and 1b [15, 16].
It is important to note that for a signiﬁcant proportion of
amino acid changes identiﬁed here, their impact on drug resis-
tance is unknown. Moreover, given the signiﬁcant nucleotide
differences between HCV genotypes and subtypes, it is
unclear whether the drug resistance mutations that have been
extensively characterized in genotype 1 would have the same
impact on resistance in other genotypic backgrounds. A recent
in vitro pilot study on the activity of the NS5A inhibitor BMS-
790052 in genotype 4, however, found overlapping resistance
proﬁles between HCV genotypes 1 and 4 [42], suggesting that
mutations analyzed here may also be important for treatment-
response rates in areas with a high HCV prevalence, such as
Africa, where HCV genotype 4 subtypes are prevalent. It is
also possible that previously uncharacterized mutations such
as the D168Q mutation prevalent in 100% of HCV genotype 3
sequences may help explain the poor treatment response of
this genotype to TMC-435 [43]. It will be important to study
the consequence of these changes in the various genetic back-
grounds on replication and resistance to antiviral drugs.
Taken together, our results indicate that deep sequencing of
full genomes from HCV-infected patients can be an efﬁci-
ent method to classify virus subtypes and may help to inform
treatment strategies. Appraisal of consensus full genome
sequence from HCV-infected individuals can be used to iden-
tify the presence of dominant antiviral drug resistance muta-
tions before initiation of a treatment regimen, while deep
sequence data can be used to identify resistance mutations
present at low frequency in the viral population of the same
individual. Our approach identiﬁed minor drug-resistant vari-
ants in a subset of the treatment-naive patients tested, while a
recent report describing the use of Illumina sequencing to
identify DAA resistance mutations in treatment-naive geno-
type 1b–infected patients showed the presence of DAA resis-
tant mutations in both NS3 and NS5B in up to 74.1% of the
patients tested [44], suggesting that these low-level mutations
may be highly prevalent in selected HCV subtypes. This infor-
mation can be used to study the impact of dominant or sub-
dominant mutations on treatment response rates for future
interferon-free treatment regimens with DAAs and to eventu-
ally steer selection of appropriate single or combinatorial anti-
viral therapies in order to minimize treatment failure due to
preexisting drug resistance mutations among viral subtypes.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org/). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages
regarding errors should be addressed to the author.
Notes
Acknowledgments. We thank the Broad Institute’s Sequencing and
Biological Samples Repository Platforms for their assistance in generation
of genomic data and sample handling.
Disclaimer. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Financial support. This work was supported by the National Institute
of Allergy and Infectious Diseases, National Institutes of Health, Depart-
ment of Health and Human Services (contract HHSN272200900018C to
B. W. B., contract HHSN272200900006C to B. W. B., grant R01-AI067926
to T. M. A., and grant U19-AI082630 to T. M. A.; and the Deutsche For-
schungsgemeinschaft (grant DFG KU2250/1-1 to T. K.).
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Murphy DG, Chamberland J, Dandavino R, Sablon E. A new geno-
type of hepatitis C virus originating from Central Africa. Hepatology
2007; 46 (Suppl 1):623A.
2. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a
uniﬁed system of nomenclature of hepatitis C virus genotypes. Hepa-
tology (Baltimore, Md). 2005; 42:962–73.
3. Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R,
Sabbah S. Use of sequence analysis of the NS5B region for routine gen-
otyping of hepatitis C virus with reference to C/E1 and 5′ untranslated
region sequences. Journal of Clinical Microbiology 2007; 45:1102–12.
4. Kalinina O, Norder H, Magnius LO. Full-length open reading frame
of a recombinant hepatitis C virus strain from St Petersburg: proposed
30 • JID 2013:208 (1 July) • Newman et al
mechanism for its formation. Journal of General Virology 2004;
85:1853–7.
5. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural inter-
genotypic recombinant of hepatitis C virus identiﬁed in
St. Petersburg. Journal of Virology 2002; 76:4034–43.
6. Raghwani J, Thomas XV, Koekkoek SM, et al. The origin and evolu-
tion of the unique HCV circulating recombinant form 2k/1b. Journal
of Virology 2011; 86:2212–20.
7. Moreau I, Hegarty S, Levis J, et al. Serendipitous identiﬁcation of
natural intergenotypic recombinants of hepatitis C in Ireland. Virolo-
gy Journal 2006; 3:95.
8. Bhattacharya D, Accola MA, Ansari IH, Striker R, Rehrauer WM.
Naturally occurring genotype 2b/1a hepatitis C virus in the United
States. Virology Journal 2011; 8:458.
9. Kageyama S, Agdamag DM, Alesna ET, et al. A natural inter-genotyp-
ic (2b/1b) recombinant of hepatitis C virus in the Philippines. Journal
of Medical Virology 2006; 78:1423–8.
10. Legrand-Abravanel F, Claudinon J, Nicot F, et al. New natural inter-
genotypic (2/5) recombinant of hepatitis C virus. Journal of Virology
2007; 81:4357–62.
11. Noppornpanth S, Lien TX, Poovorawan Y, Smits SL, Osterhaus AD-
MEHaagmans BL. Identiﬁcation of a naturally occurring recombinant
genotype 2/6 hepatitis C virus. Journal of Virology 2006; 80:7569–77.
12. Kuiken C, Simmonds P. Nomenclature and numbering of the hepatitis
C virus. Methods in Molecular Biology 2009; 510:33–53.
13. Morel V, Fournier C, François C, et al. Genetic recombination of the hepa-
titis C virus: clinical implications. Journal of Viral Hepatitis 2011; 18:77–83.
14. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with
peginterferon and ribavirin reduces HCV RNA in patients with
chronic genotype 2 but not genotype 3 infections. Gastroenterology
2011; 141:881–889 e1.
15. Fridell RA, Wang C, Sun J-H, et al. Genotypic and phenotypic analy-
sis of variants resistant to Hepatitis C Virus nonstructural protein 5A
replication complex inhibitor BMS-790052 in humans: in vitro and in
vivo correlations. Hepatology 2011; 54:1924–35.
16. Hazuda D, Ogert R, Howe J, et al. Analysis of resistance associated
variants by HCV genotype 1 subtype (1a/1b) in phase 3 (SPRINT-2/
RESPOND-2) boceprevir plus standard of care clinical trials. In: Sixth
International AIDS Society Conference on HIV Pathogenesis, Treat-
ment and Prevention, Rome, Italy, 2011.
17. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant
resistance mutations to hepatitis C virus protease and polymerase in-
hibitors in treatment-naive patients. Hepatology 2008; 48:1769–78.
18. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antivi-
ral agents for hepatitis C genotype 1. New England Journal of Medi-
cine 2012; 366:216–24.
19. Gane EJ, Stedman CA, Hyland RH, et al.. Once daily PSI-7977 plus
RBV: pegylated interferon-ALFA not required for complete rapid viral
response in treatment-naive patients with HCV GT2 or GT3. In: The
Liver Meeting 2011: American Association for the Study of Liver Dis-
eases (AASLD) 62nd Annual Meeting, Boston, MA, 2011.
20. Kuntzen T, Berical A, Ndjomou J, et al. A set of reference sequences
for the hepatitis C genotypes 4d, 4f, and 4k covering the full open
reading frame. Journal of Medical Virology 2008; 80:1370–8.
21. Henn MR, Boutwell CL, Charlebois P, et al. Whole genome deep se-
quencing of HIV-1 reveals the impact of early minor variants upon
immune recognition during acute infection. PLoS Pathogens 2012; 8:
e1002529.
22. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy
and high throughput. Nucleic Acids Research 2004; 32:1792–7.
23. Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P.
RDP3: a ﬂexible and fast computer program for analyzing recombina-
tion. Bioinformatics 2010; 26:2462–3.
24. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immu-
nodeﬁciency virus type 1 genomes from subtype C-infected sero-
converters in India, with evidence of intersubtype recombination.
Journal of Virology 1999; 73:152–160.
25. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phyloge-
netic analyses with thousands of taxa and mixed models. Bioinfor-
matics 2006; 22:2688–90.
26. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S.
MEGA5: molecular evolutionary genetics analysis using maximum
likelihood, evolutionary distance, and maximum parsimony methods.
Molecular Biology and Evolution 2011; 28:2731–9.
27. Macalalad AR, Zody MC, Charlebois P, et al. Highly sensitive and spe-
ciﬁc detection of rare variants in mixed viral populations from mas-
sively parallel sequence data. PLoS Comput Biol 2012; 8:e1002417.
28. Demetriou VL, Kostrikis LG. Near-full genome characterization of un-
classiﬁed hepatitis c virus strains relating to genotypes 1 and 4.
Journal of Medical Virology 2011; 83:2119–27.
29. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C
virus variants with decreased sensitivity to NS3.4A protease inhibitors
in treatment-naive subjects. Journal of Infectious Diseases 2008;
198:800–7.
30. Yang W, Zhao Y, Fabrycki J, et al. Selection of replicon variants
resistant to ACH-806, a novel hepatitis C virus inhibitor with no
cross-resistance to NS3 protease and NS5B polymerase inhibitors. An-
timicrobial Agents and Chemotherapy 2008; 52:2043–52.
31. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance proﬁle of the
hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrobial
Agents and Chemotherapy 2010; 54:1878–87.
32. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM.
Complete nucleotide sequence of a type 4 hepatitis C virus variant,
the predominant genotype in the Middle East. Journal of General Vi-
rology 1997; 78 (Pt 6):1341–7.
33. Cummings MD, Lindberg J, Lin TI, et al. Induced-ﬁt binding of the
macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A
protease target. Angew Chem Int Ed Engl 2010; 49:1652–5.
34. Li C, Lu L, Wu X, et al. Complete genomic sequences for hepatitis C
virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t.
Journal of General Virology 2009; 90:1820–6.
35. Pang PS, Planet PJ, Glenn JS. The evolution of the major Hepatitis C
genotypes correlates with clinical response to interferon therapy. PLoS
ONE 2009; 4:e6579.
36. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline
with once daily TMC435: a phase I study in healthy volunteers and
hepatitis C patients. Gastroenterology 2010; 138:913–21.
37. Soriano V, Vispo E, Poveda E, et al. Directly acting antivirals against
hepatitis C virus. J Antimicrob Chemother 2011; 66:1673–86.
38. Akhavan S, Schnuriger A, Lebray P, Benhamou Y, Poynard T, Thi-
bault V. Natural variability of NS3 protease in patients infected with
genotype 4 hepatitis C virus (HCV): implications for antiviral treat-
ment using speciﬁcally targeted antiviral therapy for HCV. J Infect Dis
2009; 200:524–7.
39. Lopez-Labrador FX, Moya A, Gonzalez-Candelas F. Mapping natural
polymorphisms of hepatitis C virus NS3/4A protease and antiviral re-
sistance to inhibitors in worldwide isolates. Antiviral Therapy 2008;
13:481–94.
40. Vallet S, Viron F, Henquell C, et al. NS3 protease polymorphism and
natural resistance to protease inhibitors in French patients infected
with HCV genotypes 1-5. Antiviral Therapy 2011; 16:1093–1102.
41. Lauck M, Alvarado-Mora MV, Becker EA, et al. Analysis of hepatitis
C virus intra-host diversity Across The Coding Region by Ultra-Deep
pyrosequencing. Journal of Virology 2012; 86:3952–60.
42. Wang C, Jia L, Huang H, et al. In vitro activity of BMS-790052 on
hepatitis C virus genotype 4 NS5A. Antimicrobial Agents and Chemo-
therapy 2011; 55:3795–802.
43. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435
monotherapy in patients infected with HCV genotypes 2 to 6:
TMC435-C202, a phase IIa, open-label study. Journal of Hepatology
2012; 56:1247–53.
44. Nasu A, Marusawa H, Ueda Y, et al. Genetic heterogeneity of hepatitis
C virus in association with antiviral therapy determined by ultra-deep
sequencing. PLoS One 2011; 6:e24907.
Pyrosequencing of Rare HCV Genotypes • JID 2013:208 (1 July) • 31
